Annovis Bio, Inc.

ANVSNYSE • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
1.18 USD
↗ 0.01 (0.85%)AT CLOSE (03:59 PM EDT)
1.14
↘ 0.04 (3.39%)
POST MARKET (AS OF 08:01 PM EDT)
Post Market
AS OF 08:01 PM EDT
1.14
↘ 0.04 (3.39%)
🔴Market: CLOSED

Annovis Bio, Inc. (ANVS) trades at $1.18 per share. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (1164.0%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment.

Technical & fundamental data as of Oct 2, 2026.

Open?$1.19
High?$1.20
Low?$1.14
Prev. Close?$1.17
Volume?648.5K
Avg. Volume?1.2M
VWAP?$1.16
Rel. Volume?0.56x
Bid / Ask
Bid?$1.14 × 100
Ask?$1.18 × 100
Spread?$0.04
Midpoint?$1.16
Valuation & Ratios
Market Cap?50.4M
Shares Out?42.7M
Float?30.3M
Float %?87.3%
P/E Ratio?N/A
P/B Ratio?-11.84
EPS?-$1.16
Dividend?0.00%
Ex-Dividend?N/A
RelatedALXO
News
Profile
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Themes
Biotech - Drug Development›Neuroscience & CNSLongevity & Aging›Age-Related Therapeutics
Employees
7
Market Cap
50.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.annovisbio.com
Listed
2020-01-29
Address
101 LINDENWOOD DRIVE, SUITE 225
MALVERN, PA 19355
Phone: 484-875-3192
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
21
Piotroski F-Score?0/9Weak
Altman Z-Score?-17.87Distress
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.90%High
Short Interest?6.0M
Days to Cover?3.2
Free Float30.3M
Avg Daily Volume1.9M
Settlement Date2026-09-15
Financial Health
Current Ratio?3.47Strong
Quick Ratio?3.47Strong
Cash Ratio?2.95Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
-11.84CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
97
1,164.0%STRONG▾
ROA?
S&P
3
-224.7%WEAK▾
Cash Flow & Enterprise
FCF?$-43339894
Enterprise Value?$31.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist